Lilly’s Foundayo Reaches 1,390 Patients in First Week, Trailing Novo’s Oral Wegovy Launch

Why It Matters

Foundayo’s launch tests Lilly’s ability to challenge Novo’s dominance in the fast‑growing oral obesity market, with commercial success crucial for the company’s growth trajectory and investor confidence.

Key Takeaways

• Foundayo filled 1,390 prescriptions in first two days of launch
• Novo's oral Wegovy reached over 3,000 patients in its first week
• FDA flagged heart and liver safety risks, requiring post‑marketing studies
• RBC expects Foundayo to hit 50% of Wegovy's early trajectory
• Lilly's Q1 earnings will reveal deeper commercial momentum

Pulse Analysis

The obesity‑treatment landscape is undergoing a shift as oral formulations gain traction over injectable options. Novo Nordisk’s Wegovy pill set a high bar earlier this year, quickly amassing thousands of new patients and cementing the company’s lead in the segment. Lilly’s entry with Foundayo, a tirzepatide‑based oral agent, arrives amid heightened expectations because the same molecular platform powers its successful diabetes and weight‑loss drugs Mounjaro and Zepbound. By securing FDA approval on April 1, Lilly positions itself to capture a share of a market projected to exceed $30 billion globally within the next decade.

Early prescription data, however, paint a nuanced picture. RBC Capital Markets highlighted that Foundayo’s 1,390 scripts reflect only two days of capture, whereas Wegovy’s 3,000‑plus scripts span five days. Adjusted for timing, the launch may be on a comparable trajectory, but analysts caution that early numbers are not definitive. Compounding the uncertainty, the FDA’s approval letter cited unexpected cardiac and hepatic safety signals, mandating rigorous post‑marketing surveillance. A recent Phase 3 diabetes trial alleviated some concerns, showing no increase in major adverse cardiovascular events or liver injury, yet the drug’s long‑term safety profile remains a focal point for clinicians and payers.

For investors, Foundayo’s performance will be a litmus test for Lilly’s diversification beyond its injectable portfolio. The company’s Q1 2026 earnings, due April 30, will likely feature detailed commentary on prescription trends, market uptake, and any emerging safety data. Should Foundayo achieve at least half of Wegovy’s early growth rate, analysts view it as a positive signal, potentially unlocking new revenue streams and reinforcing Lilly’s competitive stance against Novo. Conversely, slower adoption or safety setbacks could dampen the stock’s momentum, underscoring the high stakes of this inaugural oral obesity launch.